Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection

NCT03866187 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
236
Enrollment
INDUSTRY
Sponsor class

Stopped Following the primary phase (24 weeks post last vaccination) the predefined efficacy endpoint was not met. Noting the lack of efficacy and with the objective to prioritize participants' safety GSK has decided on the early termination of the study.

Conditions

Interventions

Sponsor

GlaxoSmithKline